Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Excellence Hub for Advancing Innovation in Gene Therapy

Project description

Cross-sectoral excellence hub advancing gene therapies

Gene therapy – changing or replacing faulty genes to prevent, treat or cure diseases – has shown tremendous promise in many areas but exploiting its full potential has faced challenges. The EU-funded GeneH project aims to create an excellence hub in gene therapy focused on life-threatening or chronically debilitating diseases that are considered incurable. The project’s core academic partners in Portugal and Slovenia have successful partnerships with industry, hospitals, policymakers, ecosystem/innovation supporters and patient associations. Through a cross-sectoral, multidimensional approach, the team will tackle challenges in research and development, translation, investment, regulatory and ethical issues while also providing educational and training programmes and engaging with society. Ultimately, GeneH plans to pave the way to clinical trials of innovative gene therapies.

Objective

GeneH proposes to create an excellence hub in gene therapy through strategic partnerships within and beyond Widening countries. Despite gene therapy's recognized priority in genomic medicine and its potential for high-curative economic impact, challenges persist in its development process, from conceptualization to commercialization. GeneH intends to address these challenges by serving as a catalyst for overcoming barriers and expediting research translation.
To achieve this, GeneH will establish a robust and sustainable hub that builds upon already established ecosystems in the field and recent H2020 WIDENING projects to implement centers of excellence in gene therapy (GeneT in PT and CTGCT in SL). The academic partners at its core, namely, the University of Coimbra (UC) in Portugal and the National Institute of Chemistry (KI/NIC) in Slovenia , have reached substantial achievements by partnering with industry (Bluepharma, Biocant Park, Biosistemika, Jafral), hospitals (CHUC EPE), policy makers (CCDRC, RRA LUR), ecosystem/innovation supporters (SIH EEIG, IPN), and patient associations (APAHE, ZOPS). Partners in the two ecosystems share a common goal: treating life-threatening or chronically debilitating diseases considered incurable. By harnessing the combined expertise and resources of its partners, GeneH aims to drive cross-sectoral collaboration through its 4-helix network, in a multidimensional approach that will gather further investment, address ethical and regulatory aspects, implement de-risking approaches, educational and training programes, joint R&I programs, and prepare the path for clinical trials of new gene therapy products, while actively engaging society.
By positioning itself as a leading hub in gene therapy, in line with regional, national, and European strategies, GeneH seeks to contribute to European competitive leadership globally, advancing healthcare, fostering economic growth, and making a positive societal impact.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-WIDERA-2023-ACCESS-07

See all projects funded under this call

Coordinator

UNIVERSIDADE DE COIMBRA
Net EU contribution
€ 1 793 286,25
Address
PACO DAS ESCOLAS
3004-531 Coimbra
Portugal
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 793 286,25

Participants (12)